Polyheal Announces Positive Clinical Results of its Lead Product, "Polyheal-1", for the Treatment of Chronic Wound Healing
Polyheal achieved the primary and secondary endpoints of the study. More Polyheal patients achieved coverage with red granulation tissue than the control (65% vs. 19%, p= 0.0006). Polyheal patients had greater 4 week surface area reduction (40% vs. 15%, p = 0.02) than control. The number of wounds that closed completely in the Polyheal group was twice that of the control group. No significant side effects were observed in connection with "Polyheal-1".
“This trial is unique in that it took deep complex ulcers that had failed to respond to available treatments and demonstrated improvement rates that we would expect to see in superficial ulcers. This is particularly important since it is precisely these complex wounds that put patients at greatest risk of complications such as infection and amputation,” says Prof Jan Apelqvist, at the Diabetic Foot Center in Malmö, Sweden and an international expert in the field of wound healing. “These encouraging preliminary clinical results put Polyheal among the most promising new wound healing technologies in an area with a substantial need of additional treatment strategies.”
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.